Inotec AMD, Cambridge, UK, whose product NATROX® O2 is a topical oxygen therapy (cTOT) for advanced wound care, recently announced the successful close of a $33 million Series C financing round. The funding, led by existing investors, Amadeus Capital Partners, Meltwind, Puhua Capital, and the Wealth Club, marks a major milestone in the company’s mission to heal every chronic wound and improve patients’ lives on a global scale.
The proceeds from this round will be strategically used to secure national reimbursement in the US for NATROX O2, ensuring broader accessibility for patients. Additionally, the funds will support the expansion of the company’s leadership team, strengthening its global capabilities to drive future growth and innovation.
